Trial · NCT01495910
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The minimum dose of abiraterone acetate required to decrease serum androstenedione to the age-appropriate range for adult women with 21-hydroxylase deficiency | Up to Day 7 of each treatment period. | Normalization or reduction of age-appropriate androstenedione levels will be determined by the mean of the androstenedione values measured on Study Days 6 and 7 of the treatment period. |
| Secondary | Mean serum concentrations of androstenedione | Up to Day 8 of each treatment period. | |
| Secondary | Mean serum concentrations of 17-hydroxyprogesterone | Up to Day 8 of each treatment period. | |
| Secondary | Mean plasma concentrations of renin activity | Up to Day 8 of each treatment period. | |
| Secondary | Mean serum concentrations of testosterone | Up to Day 8 of each treatment period. | |
| Secondary | Urine concentrations of androsterone | Up to Day 8 of each treatment period. | |
| Secondary | Urine concentrations of etiocholanolone | Up to Day 8 of each treatment period. | |
| Secondary | Maximum plasma concentration (Cmax) of abiraterone | Up to Day 8 of each treatment period. | |
| Secondary | Time to reach the maximum plasma concentration (tmax) of abiraterone | Up to Day 8 of each treatment period. | |
| Secondary | Area under the plasma concentration-time curve from time 0 to 24 hours postdose (AUC24) of abiraterone | Up to Day 8 of each treatment period. | |
| Secondary | Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration (AUClast) of abiraterone | Up to Day 8 of each treatment period. | |
| Secondary | Time to last quantifiable plasma concentration (Tlast) of abiraterone | Up to Day 8 of each treatment period. | |
| Secondary | Elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of abiraterone | Up to Day 8 of each treatment period. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01495910/registered